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Running title: CDKN2A deletion in childhood ALL
ABSTRACT 
Inactivation of the tumour suppressor gene, CDKN2A, can occur by deletion, methylation or 
mutation. We assessed the principal mode of inactivation in childhood ALL and frequency in 
biologically relevant subgroups. CDKN2A mutation or methylation was rare whereas genomic 
deletion occurred in 21% BCP-ALL and 50% T-ALL patients. SNP arrays revealed copy number 
neutral (CNN) LOH in 8% patients. Array CGH (aCGH) demonstrated that the mean size of 
deletions was 14.8Mb and biallelic deletions comprised a large and small deletion (mean sizes 
23.3Mb & 1.4Mb). Among 86 patients tested by FISH and SNP/aCGH, only two small deletions 
(0.025Mb & 0.05Mb) were below the resolution of detection by FISH. Patients with high 
hyperdiploidy, ETV6-RUNX1 or 11q23/MLL rearrangements had low rates of deletion (11%, 15%, 
13%) whereas patients with t(9;22), t(1;19), TLX3 or TLX1 rearrangements had higher frequencies 
(61%, 42%, 78% and 89%). In conclusion, CDKN2A deletion is a significant secondary abnormality in 
childhood ALL strongly correlated with phenotype and genotype. The variation in the incidence of 
CDKN2A deletions by cytogenetic subgroup may explain its inconsistent association with outcome. 
The discovery of CNN LOH without apparent CDKN2A inactivation suggests the presence of 
other relevant genes in this region. 
 
INTRODUCTION 
Genetic alterations including chromosomal translocation, promoter hypermethylation, somatic 
mutation and gene deletion are believed to play a key role in oncogenesis. Alterations of the 9p21 
locus have been implicated in many types of cancer, indicating a role for the tumour suppressor 
genes CDKN2A (MTS1) and CDKN2B (MTS2), which encode for p16INK4a/p14ARF and p15INK4b, 
respectively.1 Loss of cell proliferation control and regulation of cell cycle are known to be critical 
to cancer development.2 Both p16INK4a and p15INK4b specifically inhibit cyclin/CDK-4/6 complexes 
that block cell division during the G1/S phase of the cell cycle.3  
 
It has been reported that CDKN2A and CDKN2B are frequently inactivated in various 
haematological malignancies.1,4 Loss of heterozygosity (LOH) of chromosome arm 9p, including 
the CDKN2A locus, is one of the most frequent genetic events in childhood acute lymphoblastic 
leukaemia (ALL) suggesting inactivation of the second allele or, possibly, haplo-insufficiency.5-8 
Haplo-insufficiency of a tumour suppressor gene, e.g. CDKN2A, has been shown to be adequate to 
promote tumour progression.9-11 Homozygous deletion of CDKN2A has been suggested as the 
dominant mechanism of its inactivation in leukaemogenesis.12 However, the reported frequencies 
of both hetero- and homozygous deletions in childhood ALL vary, 9-27% and 6-33% in B-cell 
precursor (BCP) ALL and 7-18% and 30-83% in T-ALL, respectively.13 Similarly, the frequency of 
hypermethylation of the CDKN2A promoter has been reported to vary from 0-40% in childhood 
ALL.14-19 Although mutations in exons 1 and 2 of CDKN2A have been described in childhood ALL, 
their incidence appears to be low, ranging from 0-7%.12,20-24 
 
As reported data on CDKN2A alterations in childhood ALL are discrepant, it remains important to 
reveal the role of this gene in cancer development. In this study we have used mutation and 
methylation analyses as well as genomic technologies to elucidate the principal mode of CDKN2A 
inactivation in childhood ALL. Moreover, the use of array based comparative genomic 
hybridisation (aCGH) and single nucleotide polymorphism (SNP) microarray mapping has allowed 
the architecture of CDKN2A deletions in this disease to be characterised. Finally, extensive 
screening using fluorescence in situ hybridisation (FISH) has enabled the frequency of deletions to 
be accurately determined in biologically relevant subgroups.  
 
MATERIALS AND METHODS 
Patient samples 
Diagnostic or relapse samples were obtained from patients entered to a NCRI Childhood Cancer 
and Leukaemia Group (CCLG) treatment trial (UKALLXI, ALL97, or ALL2003) or treated locally 
within the Northern Region of the UK after informed consent was obtained in accordance with 
the Declaration of Helsinki. All patients were diagnosed between 1986 and 2007. Cytogenetic and 
FISH data from diagnostic and relapse samples were collected either by the LRF UKCCG 
Karyotype Database25 or the NHS Northern Genetics Service. Institutional Review Board 
approval was provided by each participating institution. Peripheral blood lymphocytes were 
obtained from a healthy individual for use as a normal control. Genomic DNA was extracted from 
mononuclear cells after density gradient centrifugation using a commercial kit (QiAmp DNA 
Blood Kit, Qiagen, USA), according to the manufacturer’s instructions. 
 
Mutation analysis 
PCR amplification for each exon was performed in 50 µl volume assays containing 1 X PCR buffer, 
200 µM of dNTP mix, 1.5-2.5 mM MgCl2, 0.2-0.4 µM of each primer, 1.25U of Amplitaq Gold 
polymerase and 100 ng of genomic DNA. In addition, a final concentration of 2.5% dimethyl 
sulfoxide (DMSO) was used in the exon 2 reaction mixture. Primer pairs for exon 1, 2 and 3 were 
previously described.20,26 PCR conditions for exon 1 and 2 consisted of initial denaturation at 95°C 
for 10 minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 56°C 
for 30 seconds and extension at 72°C for 30 seconds. The final extension at 72°C was performed 
for 5 minutes. PCR amplification of exon 3 was carried out using Touchdown protocol consisting 
of initial denaturation at 95ºC for 10 minutes, followed by 14 cycles (20 sec denaturation at 94ºC, 
1 min annealing at 65-58ºC with a decrease of 0.5°C every cycle and 1 min extension at 72ºC) and 
a further 20 cycles with annealing at 58ºC for 1 min. All PCR products were resolved on 2% 
agarose gels stained with ethidium bromide and visualized under UV transillumination 
 
Mutation screening of all exons was performed using denaturing high performance liquid 
chromatography (dHPLC) (WAVE® Nucleic Acid Fragment Analysis System, Transgenomic, UK). 
All PCR products showing homoduplex profiles were spiked with approximately equimolar 
proportions of a product known to contain a wild-type CDKN2A fragment, and re-screened in 
order to differentiate between wildtype homozygote and homozygote variants. DNA from a 
melanoma cell line (MM384) kindly provided by Dr. Nicholas Hayward (Queensland Institute of 
Medical Research, Australia) and a myeloid leukaemia cell line (HL60), known to contain CDKN2A 
mutations were used as positive controls for exon 1a and 2, respectively. Heteroduplex profiles 
for MM384 and HL60 cell lines were detected after spiking consistent with their homozygous 
mutant status. All samples showing an altered dHPLC profile were directly sequenced or cloned 
and then sequenced using standard methods (Pinnacle Lab., Newcastle University, UK). 
 
Methylation analysis 
The methylation status of the CDKN2A promoter regions was assessed by methylation specific-
PCR (MSP) analysis. DNA modification (bisulphite treatment) was conducted by using CpGenome 
DNA Modification Kit (Chemicon   International, CA). A total of 250 ng DNA was treated 
according to the manufacturer’s protocol. DNA from Raji and HL60 cell lines were used as 
controls for methylated and unmethylated CDKN2A, respectively, as previously described.3 All 
bisulphite-treated DNA samples were amplified by using the primer sets specific for the 
unmethylated and methylated CDKN2A sequences (referred to as p16U and p16M respectively),  
as previously reported.27 The final concentration of the reagents in the PCR mixture were 1 X 
PCR buffer, 200 µM dNTP mix, 1.5 mM MgCl2, 0.2 µM of each primer set for p16U and p16M, 
1.25U of Amplitaq Gold polymerase and bisulphite-modified DNA (50 ng) in a final volume of 25 
µl. PCR conditions were as follows: initial denaturation at 95ºC for 10 minutes, followed by 14 
cycles (20 sec denaturation at 94ºC, 1 min annealing at 64-57ºC with a decrease of 0.5ºC every 
cycle and 1 min extension at 72ºC) and a further 32 cycles with annealing at 57ºC for 1 min. Each 
PCR product was directly loaded onto 1.8% agarose gel, stained with ethidium bromide and 
visualised under UV transillumination. MSP analysis was repeated for each patient sample to 
confirm the methylation status of CDKN2A.  
 
Single nucleotide polymorphism mapping array (SNPA) 
DNA samples at relapse and presentation were analysed using a GeneChip Human Mapping 10K 
and/or 50K array (Affymetrix UK Ltd, High Wycombe, UK) to characterize LOH and allele copy 
number. Each SNP on the array is represented by 40 different 25bp oligonucleotides, each with 
slight variations which allow accurate genotyping. Sample analysis was performed by MRC 
Geneservice (Hinxton, Cambridge, UK). Data from microarray analysis were analysed using the 
Copy Number Analyser for Affymetrix® GeneChip (CNAG) software package (version 1.1), to 
identify regions of chromosomal deletion, amplification or LOH.28 
 
Array based comparative genomic hybridisation (aCGH) analysis 
aCGH was performed with array platforms constructed from either large-insert DNA clones or 
oligonucleotides, offering genome coverage at 1Mb and 6Kb intervals, respectively. For the large 
insert arrays, DNA samples were processed in a dye-swap combination and sex-matched with 
DNA extracted from phenotypically normal individuals (Promega, Southampton, UK) before 
hybridization to two commercially available systems (Spectral Genomics and IntegraGen, 
Genosystems, Paris, France), as previously reported.29 For the oligonucleotide array, sample DNA 
was sex-matched to the same control DNA and hybridized to the 244K whole genome array 
(Agilent Technologies, Santa Clara, California, USA) according to manufacturer’s instructions.30 
Scanning, grid placement, spot quality, data normalization, fluorescence quantification, post-
processing of the array image and data analysis were performed as previously described.31,32 
Regions of copy number alteration (CNA), identified by the large-insert array, were defined as a 
minimum of three adjacent clones simultaneously deviating beyond the threshold values in both 
dye-swap experiments and were positioned onto the human genome sequence using BlueFuse 
software (BlueGnome, Cambridge, UK). For the oligonucleotide array analysis, CGH Analytics 
software (Agilent Technologies, Santa Clara, California, USA) was used to identify regions of CNA 
based on the z-score and mathematical aberration detection analysis (ADM1, Agilent 
Technologies). 
 Fluorescence in situ hybridization (FISH) 
FISH analysis was performed on frozen cytospins and/or fixed cells from diagnostic bone marrow. 
Three commercial probes were used to detect CDKN2A deletions in leukaemic cells: LSI® p16 
(9p21) SpectrumOrange™/CEP® 9 SpectrumGreen™ Probe (Vysis/Abbott Diagnostics, 
Maidenhead, UK);  P16 Deletion Probe (Cytocell Technologies Ltd., Cambridge, UK); p16 
(CDKN2A) specific probe (Qbiogene/MP Biomedicals, Cambridge, UK). Probe and slide 
preparation as well as hybridization and washing steps were performed according to the 
manufacturers’ protocols. An additional home-grown dual-colour, CDKN2A deletion probe 
(consisting of BAC RP11-149I2/70L8 and the chromosome 9 centromere probe pMR9A; all clones 
from Sanger Institute, Hinxton, UK) (Wessex Regional Genetics Laboratory, WRGL) was also 
used. These were grown and labelled for FISH as previously described.33 The approximate size of 
the p16/CDKN2A probes are: Vysis - 190kb; Cytocell – 101kb; Qbiogene – not available; WRGL – 
101kb. A minimum of 100 interphase cells were scored in each test. A signal pattern of two red 
and two green (2R2G) was considered to represent a normal cell. Loss of one signal 
corresponding to the test and retention of both signals for the control probe (i.e. 1R2G or 2R1G 
depending on the probe) was considered to represent a heterozygous deletion. A homozygous 
deletion was defined as loss of both test signals with retention of both control signals (i.e. 0R2G 
or 2R0G depending on the probe). The cut-off level defined to rule out a false positive result was 
calculated to be 5%. Therefore, only abnormal cell populations comprising more than 5% of 
analysed cells were included. Rare cases with two different deleted populations (one heterozygous 
and one homozygous) were classified as having a homozygous deletion. Cases with loss of a whole 
chromosome 9 were not classified as having a deletion.  
 
RESULTS 
Mutation screening 
Mutation screening of all three exons was successfully performed on 47 patients who were known 
to have retained (by FISH or SNPA) at least one CDKN2A allele. Samples tested were from 
diagnosis (n=21), relapse (n=25) or both time points (n=1) (Table 1). Chromatography profiles 
generated from dHPLC were inspected to detect heteroduplexes which indicated the presence of 
mutations/polymorphisms. All aberrant profiles were confirmed by DNA sequencing analysis. A 
known SNP was detected in 15 (32%) patients; detected at diagnosis (n=4), relapse (n=10) or 
both time points (n=1). Nine (19%) patients had the 500C>G SNP in the 3’UTR of exon 3: 7 
(15%) patients were CG heterozygotes while 2 (4%) were GG homozygotes. Three patients who 
were CG heterozygotes at nucleotide 500 also carried the A148T polymorphism in exon 2. Six 
(13%) patients had the 540C>T polymorphism in the 3’UTR of exon 3: 4 (9%) patients were CT 
heterozygotes while 2 (4%) were TT homozygotes. Only one patient (L5C) harboured a somatic 
mutation. This was detected in a relapse sample and involved a base substitution of C>T in exon 2 
at nucleotide 247, which resulted in the amino acid tyrosine replacing histidine at codon 83 
(H83Y). Although this relapse sample showed an aberrant profile after dHPLC, initially no 
mutation was detected by sequencing analysis. DNA  from this patient was cloned and after re-
sequencing the mutation was confirmed in 2/20 clones; suggesting that the quantity of mutant 
DNA was too low to be detected by first direct sequencing. We concluded that only a minority of 
the blast cells harboured this mutation which was detected by the sensitive dHPLC technique but 
not by direct sequencing, in agreement with a previous study.34 This patient had a normal 
karyotype and did not show loss of CDKN2A by FISH. However, SNP array analysis (see below) 
revealed copy number neutral LOH from 9p21.1 to the telomere. 
 
Methylation screening 
MSP analysis was performed on a total of 99 patients who were known to have retained (by FISH 
or SNPA) at least one CDKN2A allele (Table 1). Samples tested were from diagnosis (n=70), 
relapse (n=26) or both time points (n=3). Each assay was performed twice and included a positive 
control (Raji cell line in which CDKN2A is methylated) and a negative control (HL60 cell line in 
which CDKN2A is unmethylated). The presence of a 151 bp and a 150bp product in the relevant 
lane indicated that the sample was umethylated (U) and methylated (M) respectively. None of the 
patients showed complete methylation of the CDKN2A promoter but one patient (L450) had 
partial methylation as shown by the presence of both U and M products. Partial methylation 
suggests the presence of a mixed population of blasts: one with and one without methylation of 
the CDKN2A promoter. This patient had a normal karyotype, did not have a mutation and had an 
intact 9p by aCGH (see below). 
 
Genomic analyses 
High density SNPA analyses were performed on 98 patients at diagnosis (n=78), relapse (n=12) or 
both time points (n=8) (Table 1). No abnormality of the short arm of chromosome 9 was 
detected in 73 (74%) patients whereas 25 (26%) patients harboured either a deletion (n=17) or 
CNN LOH (n=8) of 9p. The absence of a 9p deletion was confirmed in 27 patients by FISH (n=8), 
aCGH (n=11) or both techniques (n=8). SNPA revealed a deletion of 9p in 17 (17%) patients 
(Figure 1Ai-iii). Most of the deletions were terminal [n=11: del(9)(p12)x1, del(9)(p13.1)x1, 
del(9)(p13.2)x1, del(9)(p13.3)x4, del(9)(p21.2)x1 and del(9)(p21.3)x3] but interstitial deletions also 
occurred [n=6: del(9)(p21.2p21.3)x1, del(9)(p21.3p22.1)x2, del(9)(p21.3p22.3)x1, 
del(9)(p21.3p21.3)x2]. All the deletions were confirmed by FISH (n=10), aCGH (n=2) or both 
techniques (n=5). In addition to these deletions, SNPA revealed CNN LOH (also known as 
acquired isodisomy and uniparental disomy) in 8 (8%) patients at diagnosis (n=6) and relapse 
(n=2). The area of CNN LOH (Figure 1Aiv) ranged from ~28Mb to the whole chromosome: 
9p21.1->9pter (n=2), 9p13->9pter (n=1), 9q21->9pter (n=1) and whole chromosome 9 (n=4). 
None of these patients showed a CDKN2A deletion by FISH (n=7 tested) or promoter 
hypermethylation (n=8). However, one patient did harbour a H83Y mutation in exon 2 of 
CDKN2A (see above). A high hyperdiploid karyotype was detected in 5 of these 8 patients, 
including 3 of the 4 patients with whole chromosome 9 CNN LOH but 2 normal copies of 
chromosome 9 was seen by cytogenetics. Cytogenetics failed or was normal in the remaining 3 
patients. 
 
A selected series of patients (n=105) were analysed using aCGH at diagnosis (n=102), relapse 
(n=2) or both time points (n=1) (Table 1, Figure 1B). Overall 34 (32%) patients harboured a 
deletion of CDKN2A, including 15 which showed biallelic loss (Figure 2). FISH analysis confirmed 
the presence of a CDKN2A deletion in 19/20 (95%) patients tested. One patient (patient 10026) 
showed a very small (0.045Mb) monoallelic deletion of CDKN2A which was below the resolution 
of the commercial or home-grown FISH probes. In another patient (patient 2741), aCGH 
detected a large (36.7Mb) monoallelic deletion accompanied by a very small (0.025Mb) biallelic 
deletion, the latter of which was below the resolution of either FISH probe. The size of the 
deletions varied considerably from 0.025Mb to 39.1Mb, with a mean of 14.5Mb and median of 
7.3Mb. Among 15 patients with biallelic deletions, a pattern of one large and one small deletion 
was evident (Figure 2). The mean size of the larger deletion was 23.3Mb whereas the smaller 
deletion was more focal with a mean size of 1.4Mb: 7/15 biallelic deletions were less than 1Mb.  
 
Correlation of CDKN2A deletions with demographic and cytogenetic features 
In order to assess the true incidence of CDKN2A deletions in childhood ALL as a whole and within 
relevant biological subgroups, an extensive interphase FISH screening programme was carried out. 
Three independent and unbiased cohorts were identified as follows: 864 diagnostic samples from 
patients with BCP-ALL; 266 diagnostic samples from patients with T-ALL; and a relapse cohort 
comprising 69 BCP-ALL and 8 T-ALL patients. A total of 1,207 samples were screened with one 
of four FISH probes: Vysis, Cytocell, Qbiogene and WRGL (see methods and Table 1). However, 
the majority of samples (96%) were tested with either the Vysis probe (n=515), WRGL probe 
(n=870) or both (n=216). Among 226 samples tested with more than one FISH probe, only 11 
(<5%) cases showed discrepant results. In 4 cases the WRGL probe detected a biallelic deletion 
where the Vysis probe had detected only a monoallelic deletion. In the other 7 cases, no deletion 
was detected by the Vysis probe whereas the WRGL or Qbiogene probe detected a monoallelic 
(n=5) or biallelic (n=2) deletion. These discrepancies are due to the fact that the Vysis probe is 
~90kb larger than the WRGL or Qbiogene probes. Conventional cytogenetics was attempted on 
virtually all these samples (1197/1207, 99%) and was of sufficient quality to assess 9p status in 884 
(73%). A cytogenetically visible 9p deletion/abnormality was detected in 133/277 (48%) samples 
where FISH detected a deletion. In a small number of samples (n=19) a cytogenetically visible 9p 
abnormality did not correlate with a deletion of CDKN2A.  
 
The incidence of CDKN2A deletions and the proportion of biallelic deletions present at diagnosis 
were higher in T-ALL patients compared to BCP-ALL patients: 50% v 21% (p<0.001) & 62% v 43% 
(p=0.001), respectively (Table 2). Among BCP-ALL patients, CDKN2A deletions were more 
prevalent among older children (10+ years, p<0.001) and those with a white cell count (WCC) of 
greater than 50x109/L (p<0.001). However, this was not the situation among T-ALL patients 
(Table 2). Moreover, within the BCP-ALL and T-ALL cohorts the incidence of CDKN2A deletions 
was associated with specific cytogenetic subgroups. The incidence of deletions was significantly 
lower among BCP-ALL patients with the ETV6-RUNX1 fusion or high hyperdiploidy, whereas it 
was significantly higher among patients with t(9;22)(q34;q11) or t(1;19)(q23;p13) (Table 2). Among 
T-ALL patients, those with involvement of TLX1 or TLX3 had significantly higher rates of deletion 
when compared with T-ALL patients without these abnormalities (Table 2). Considering BCP-ALL 
and T-ALL patients together, CDKN2A deletions were rare among those with MLL translocations 
[4/33 (12%) v 285/1012 (28%), p<0.05]. However, the difference was not significant when BCP-
ALL and T-ALL patients were considered separately (Table 2). Among 10 patients with 
t(4;11)(q21;q23) only one had a homozygous deletion of CDKN2A and none of the 9 patients with 
t(11;19)(q23;p13) harboured a deletion. Despite the incidence of CDKN2A deletions varying 
markedly by immunophenotype, age, WCC and cytogenetic subgroup, the proportion of biallelic 
deletions was relatively stable: 40% among BCP-ALL and 60% among T-ALL patients. Two possible 
exceptions were t(9;22) patients with BCP-ALL and those with normal karyotypes, where 
monoallelic and biallelic deletions dominated respectively (Table 2).  
 
The incidence of CDKN2A deletions at relapse was slightly higher than that seen at diagnosis 
among BCP-ALL patients, although the difference was not statistically significantly: 21/69 (30%) v 
180/864 (21%) p=0.06. The relapse cohort comprised only 8 T-ALL patients of which only 2 (25%) 
harboured a CDKN2A deletion, however both were biallelic. Among 44 patients where we were 
able to assess CDKN2A status at both diagnosis and relapse by FISH, SNPA or aCGH, 28 (64%) 
patients had normal CDKN2A at both time points. The remaining 16 (36%) patients showed 
retention (n=9, 20%) or gain (n=7, 16%) of a CDKN2A deletion or 9p CNN LOH between 
diagnosis and relapse. The 7 CDKN2A abnormalities acquired at relapse comprised: 2 monoallelic 
deletions, 4 biallelic deletions and 1 CNN LOH between 9p21.1 and the telomere. These 7 
patients did not have any remarkable features with respect to age at diagnosis, WCC, 
immunophenotype, karyotype or time to relapse (data not shown). Interestingly, 6 (86%) of these 
patients were male and three relapses involved the testes as well as the bone marrow. 
 
DISCUSSION 
This is the first study to utilise five separate technologies to assess the principal mode of CDKN2A 
inactivation in childhood ALL. We found that CDKN2A mutations were rare in this disease which 
agrees with most 21-24 but not all previous studies.12,20 We found only one mutation which was a C 
to T substitution in exon 2 that produced an amino acid change from histidine to tyrosine at 
codon 83 (H83Y) and has been shown to be defective in inducing cell cycle arrest.35 This H83Y 
mutation has not previously been reported in leukaemia but has been detected in bladder and 
gastrointestinal stromal tumors.36,37 Despite screening over 100 samples for hypermethylation of 
the CDKN2A promoter, we found partial methylation in only one diagnostic sample. Two previous 
studies of a similar size found CDKN2A methylation in 7% 16 and 32% 18. Several much smaller 
studies (<30 patients) have reported equally variable levels of methylation. However, it has been 
suggested recently that CDKN2A hypermethylation is not a disease specific event since it has been 
observed in the mononuclear cells from normal individuals.38 In contrast, we have demonstrated 
that genomic deletion of CDKN2A is substantially more prevalent in childhood ALL (20% in BCP-
ALL and 50% in T-ALL) than either mutation or methylation. As the cohorts we screened for 
mutation and methylation excluded cases with biallelic deletion of CDKN2A our figures are under-
estimates of the true incidence. We assessed genomic deletion by SNPA, aCGH and FISH and 
found a very high degree of concordance between the three techniques with only a handful of 
deletions detected by aCGH which were below the resolution of FISH. The apparent difference in 
detection rate between SNPA (17%) and aCGH (32%) is due to the fact that specific cytogenetic 
subgroups were selected for aCGH analysis. Therefore, we concluded that genomic deletion is 
the principal mode of CDKN2A inactivation in childhood ALL and that FISH is a reliable and 
accurate method for detecting these deletions. 
 
In order to accurately assess the incidence of mono- and biallelic deletions in childhood ALL, we 
screened two large and unbiased cohorts of BCP-ALL and T-ALL patients by FISH. Over 200 
patients were screened with more than one FISH probe and there was a high degree of 
concordance. As expected the smaller home grown WRGL probe detected a handful of smaller 
deletions that were below the resolution of the commercial probes. Despite these discrepancies 
and those detected when comparing aCGH and FISH, the numbers of patients involved were small 
and not sufficient to affect the subsequent analyses. In agreement with previous large studies,13,39,40 
we found that the incidence of CDKN2A deletions was significantly higher among T-ALL patients 
compared with BCP-ALL patients which included the proportion of biallelic deletions. Among 
BCP-ALL patients, we found a frequency of CDKN2A deletions of 21% which was the same as 
Kawamata et al41 (21%) but lower than Bertin et al 13  (31%) and Mullighan et al 39 (34%). We 
found that 50% T-ALL harboured a CDKN2A deletion, a frequency substantially lower than that 
reported by Bertin et al 13 (78%), Mullighan et al 39 (72%) and Kawamata et al 41 (78%). These 
differences are probably due to variation in the underlying patient cohort with respect to age and 
WCC rather than due to the technique employed. Firstly, evidence from our study and Usvasalo 
et al 40 indicated that the vast majority of CDKN2A deletions are detectable by FISH. Secondly, 
data from this study and Mirebeau et al 42 showed that the frequency of CDKN2A deletions varied 
according to age and presenting WCC. Our study included over 1,200 patients (more than the 
combined total from the three main previous studies), thereby minimising the effect of any slight 
variations in age or WCC distribution. 
 
The number of cases included in our study was sufficiently large to systematically address the 
relationship between CDKN2A deletions and specific cytogenetic subgroups. CDKN2A deletions 
were less frequent in patients with high hyperdiploidy and the ETV6-RUNX1 fusion compared to 
those without these abnormalities. We found a similar incidence of deletions among high 
hyperdiploidy patients as Mirebeau et al 42, but these authors found that over a third of ETV6-
RUNX1 patients had a deletion. However their result was based on fewer than 50 patients, 
whereas over 200 ETV6-RUNX1 positive patients were included in this study. In addition, we 
observed a higher incidence of CDKN2A deletions among patients with t(1;19) and t(9;22). 
Although patients with a MLL translocation were divided between the BCP-ALL and T-ALL 
cohorts, it was clear that the incidence of CDKN2A deletions was rare in this subgroup with only 
4/33 (12%) showing evidence of a deletion. Interestingly the incidence also varied within the T-
ALL cohort where patients with TLX3 or TLX1 rearrangements had a high incidence of deletion. 
In a separate study, we have recently observed a strong correlation between the presence of 
t(6;14)(p22;q32)/IGH@-ID4 and a monoallelic CDKN2A  deletion.43 
 
As in previous studies, we observed both monoallelic and biallelic CDKN2A deletions and found 
that the latter were more prevalent in T-ALL.13,40,42 Interestingly, within the BCP-ALL and T-ALL 
cohorts the proportion of biallelic deletions did not vary by age, WCC or cytogenetic subgroup, 
with the exception of t(9;22) and normal karyotypes. However these observations were based on 
relatively few cases. In our cohort, biallelic deletions comprised one large and one much smaller 
deletion. A recent aCGH/FISH study by Usvasalo40, which focussed on older children and 
adolescents, observed a similar architecture. 
 
The use of SNP arrays allowed the identification of CNN LOH, a phenomenon which has recently 
been associated with malignancy, including ALL.41,44-46 Previous studies have shown that this genetic 
mechanism is associated with the presence of homozygous mutations: JAK2 in myeloproliferative 
diseases, PTCH in basal cell carcinomas and FLT3 in AML.44,47,48 None of our CDKN2A CNN LOH 
cases were associated with deletion or methylation and only one had a CDKN2A mutation. 
However, the region of CNN LOH always encompassed numerous other genes and in half of the 
cases extended to the whole chromosome; indicating the likely involvement of other candidate 
genes such as PAX5 at 9p13.2.39 Recently, Kawamata et al41 identified a similar incidence of 9p / 
whole chromosome 9 CNN LOH (12%) among children with ALL. However, Kawamata et al 
found an association between 9p CNN LOH and CDKN2A deletion but not with whole 
chromosome 9 CNN LOH. Interesting both studies showed a strong association between 9p 
CNN LOH and high hyperdiploidy and this was particularly strong for cases with whole 
chromosome 9 CNN LOH. Therefore, it is not surprising that chromosome 9 is rarely gained in 
children with high hyperdiploidy.49  
 
The literature is divided as to the prognostic relevance of CDKN2A deletions in childhood ALL 
with some studies indicating an adverse effect50-54 while others show no effect.42,55,56 These studies 
followed several cytogenetic based reports which suggested an adverse outcome for patients with 
a cytogenetically visible 9p abnormality.57,58 The majority of patients in this study are being treated 
on an ongoing clinical trial, hence we are unable to present survival analysis. However, our results 
are highly relevant to this debate on prognosis. We have demonstrated unequivocally that the 
frequency of CDKN2A deletions is unevenly distributed across distinct cytogenetic subgroups and 
therefore any study assessing their prognostic impact must incorporate analysis stratified by 
cytogenetics. It is possible that the inconsistent results of previous studies with respect to the 
prognostic relevance of CDKN2A deletions are due to the variable frequency of deletions by 
cytogenetic subgroup. However, it is also possible that CDKN2A deletions do not represent a true 
independent prognostic factor. A large study incorporating cytogenetics and the accurate 
determination of CDKN2A deletion is required to address this important issue. We did not 
observe any difference in the incidence of CDKN2A deletion between diagnosis and relapse but 
given the small number of patients in our series a larger study will be required to definitely answer 
this question. However, we would not draw the same conclusion for T-ALL where the frequency 
of CDKN2A deletions is higher, less variable by genetic subtype and the subject of fewer analyses.  
 
In conclusion we have demonstrated that the principal mode of CDKN2A inactivation in childhood 
ALL is by genomic deletion and that FISH is an efficient detection method. Moreover, we have 
established that the frequency of deletions varies considerably by genetic subtype, especially within 
BCP-ALL where this variation is likely to account for discrepant reports as to its prognostic 
relevance. The architecture of biallelic deletions and the observation of large areas of 9p with 
disease specific CNN LOH implicate other genes within this region which are likely to be 
important, both for maintaining and initiating the leukemia phenotype. 
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Figure 1: Genomic mapping of chromosome arm 9p: (A) Profiles generated using Copy 
Number Analyser for Affymetrix® GeneChip (CNAG) software. Ideograms of chromosome 9 
are positioned vertically and flanked by a blue copy number plot to the right, which follows 2.0 
for normal copy number. To the left of each ideogram heterozygous SNP calls are shown in 
green and the likelihood of LOH is represented by the thickness of the blue bar. Thus the four 
profiles show a patient with (i) a monoallelic terminal deletion of 9p; (ii) an interstitial biallelic
deletion; (iii) both a terminal monoallelic and interstitial biallelic deletion; and (iv) copy number 
neutral LOH. (B) An array CGH profile for chromosome 9. The chromosome ideogram is 
positioned vertically with the red line following a log ratio of 0.0 for normal copy number. This 
profile shows a patient with a terminal monoallelic and interstitial biallelic deletion. The 
shaded areas define regions of copy number change according to a z-score algorithm. (C)
FISH analysis: (i-iii) Vysis p16(9p21) (red) / CEP9 (green) probe showing a (i) normal pattern, 
(ii) monoallelic deletion, or (iii) biallelic deletion. (iv-vi) WRGL CDKN2A (green) / Centromere
9 (red) deletion probe showing (iv) normal pattern, (v) monoallelic deletion, or (vi) biallelic
deletion.
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